SCHEMBL6500965

SCHEMBL6500965

CCOC(=O)c1cccc(N2CCC(Nc3ncccn3)CC2)c1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.51
NOS2 P35228 2/20 0.47
CDK1 P06493 3/20 0.44
CDK4 P11802 3/20 0.44
CCND1 P24385 3/20 0.44
CDK2 P24941 3/20 0.44
MAPK8 P45983 2/20 0.43
MAPK9 P45984 2/20 0.43
MAPK10 P53779 2/20 0.43
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 1/20 0.41
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
DRD2 P14416 1/20 0.41
DRD3 P35462 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6502007 0.81 TSHR (0.45) OPRK1ALDH1A1KMT2AMAPTHTT
SCHEMBL382601 0.81 OPRK1 (0.41) OPRK1NOS2NPC1ALDH1A1KMT2A
SCHEMBL6499370 0.80 PRKD3 (0.48) OPRK1ALDH1A1KMT2AMAPTHTT
SCHEMBL382510 0.78 NOS2 (0.51) OPRK1NOS2ALDH1A1MEN1KMT2A
SCHEMBL7471294 0.77 NOS2 (0.48) OPRK1NOS2ALDH1A1MAPTNOS3
SCHEMBL6506469 0.76 HCRTR2 (0.43) OPRK1ALDH1A1MEN1KMT2AMAPT
SCHEMBL382455 0.75 DRD2 (0.42) MAPK8MEN1KMT2ADRD2DRD3
SCHEMBL3776029 0.74 NOS2 (0.74) NOS2CDK1CDK4CCND1CDK2
SCHEMBL382149 0.74 OPRK1 (0.51) OPRK1NOS2NPC1ALDH1A1MEN1
SCHEMBL383015 0.74 OPRK1 (0.51) OPRK1NOS2NPC1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059669-A1 M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity AJITO KEIICHI (JP) 2005-03-17 US disclosed
EP-1229024-A1 m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM MEIJI SEIKA KAISHA LTD. (JP) 2002-08-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059669-A1 M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity ITGAV, ITGB3, ITGA4 OPRK1 443/4885NOS2 3444/4885CDK1 3161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.